IAB56 RPT agent is designed to target integrin αvβ6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies. IAB57 RPT agent is designed to target DLL3, a target over-expressed in cancer tissues and relevant in several cancers, most notably Small-Cell Lung Cancer (SCLC) LOS ANGELES, May 18, 2023 /PRNewswire/ … Read more
IAB56 RPT agent is designed to target integrin αvβ6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies. IAB57 RPT agent is designed to target DLL3, a target over-expressed in cancer tissues and relevant in several cancers, most notably Small-Cell Lung Cancer (SCLC) LOS ANGELES, May 18, 2023 /PRNewswire/ … Read more
– ATG-031, discovered and developed in-house by Antengene, is the world’s first anti-CD24 antibody to advance to the clinic in oncology and Antengene’s third drug candidate to enter clinical studies in the U.S. – The Phase I “PERFORM” study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031 in patients with … Read more
CHICAGO, May 17, 2023 /PRNewswire/ — The lung cancer five-year survival rate has increased by nearly 40% in the past decade. Unfortunately, this progress has not been shared equally. Black Americans with lung cancer are less likely to be diagnosed at an early stage, less likely to receive surgical treatment, and less likely to receive any … Read more
– Highly statistically significant and clinically meaningful results – – 63% mean blood Phe reduction in primary analysis population (p<0.0001) – – Conference call and webcast to be held at 8:00 AM EDT – SOUTH PLAINFIELD, N.J., May 17, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in … Read more
NEW YORK , May 17, 2023 /PRNewswire/ –A new study adds to an emerging, radically new picture of how bacterial cells continually repair faulty sections of their DNA. Published online May 16 in the journal Cell, the report describes the molecular mechanism behind a DNA repair pathway that counters the mistaken inclusion of a certain type … Read more
Partnership Will Streamline Transitions of Care With Automated Touchpoints to Reach More Patients and Unburden Care Teams SAN FRANCISCO, May 17, 2023 /PRNewswire/ — Memora Health, the leading intelligent care enablement platform, today announced a partnership with SUNY Downstate Health Sciences University. As Brooklyn’s only academic medical center for health education, research, and patient care, … Read more
Menarini Silicon Biosystems just signed a partnership with Alivio Health to provide preferred access, to their clients and members, to the minimally invasive CELLSEARCH® CTC tests so that more cancer patients may benefit from real-time information on disease status and response to therapy. BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., May 17, 2023 /PRNewswire/ — Menarini … Read more
HAYWARD, Calif., May 17, 2023 /PRNewswire/ — Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present results of a three-year study that systematically compared the recombinant adeno-associated virus (rAAV) vector products manufactured using insect Sf9 and human HEK293 cell culture systems at the 26th ASGCT annual conference in Los Angeles, … Read more
– Preclinical Data Published in the Peer-Reviewed Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator – – Nurr1 Activation Suggested to Prevent Neurodegeneration Which is Relevant in Multiple Sclerosis, Parkinson’s Disease and Beyond – NEW YORK, May 17, 2023 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline … Read more